JNJ-49095397

Cat. No.: HY-120595

CAS No.: 1220626-82-3

Molecular Formula: $C_{34}H_{36}N_6O_4$

Molecular Weight: 592.69

Target: p38 MAPK; Src

Pathway: MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (168.72 mM; Need ultrasonic)

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
1 mM	1.6872 mL	8.4361 mL	16.8722 mL
5 mM	0.3374 mL	1.6872 mL	3.3744 mL
10 mM	0.1687 mL	0.8436 mL	1.6872 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma[1].

IC_{50} & Target			
	p38α	p38γ	Haematopoietic Kinase (HCK)

In Vitro

JNJ-49095397 (RV568) (1 pg-1 μg/mL; 4 h) inhibits LPS-induced CXCL8 release in PBMCs and d-U937 cells[1].
JNJ-49095397 (1 μg-1 g/mL; 4 h) inhibits TNFα-induced interleukin (IL)-6 and CXCL8 release in a concentration-dependent manner[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

JNJ-49095397 (RV568) (1-20 μg/mouse; intratracheal; once) shows anti-inflammatory activities in LPS-induced neutrophil accumulation mouse model[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nonfasted Balb/c mice, LPS-induced neutrophil accumulation model[1]
Dosage:	1, 4 and 20 μg/mouse
Administration:	Intratracheal administration, 2, 8 or 12 h prior to LPS inhalation
Result:	Prevented the accumulation of neutrophils in the BAL fluid. Significantly inhibited neutrophil accumulation when administered up to 8 h prior to LPS inhalation.

REFERENCES

[1]. Charron CE, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017 Oct 26;50(4):1700188.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA